3. Clinical Data ( CLDA) is a biotechnology company. It has several late-stage compounds, including Vilazodone for depression and Stedivaze for cardiac stress. It also sells genetic tests to determine drug response. Its fiscal first-quarter loss narrowed to $14 million, or 51 cents a share, from a loss of $15 million, or 88 cents, a year earlier. Revenue grew 48%. Clinical Data's stock is expensive based on all relative valuation metrics since the company is consistently unprofitable. Still, all six analysts following Clinical Data recommend purchasing its shares.

If you liked this article you might like

Stocks Claw Back From Session Lows as Markets Digest North Korea Threat

North Korea Threat Resurfaces to Drag Stock Futures Lower

7 Essential Rules for Investing in Tech Stocks

Wall Street Deflates in Pullback After Fed Excitement, No Records for Dow